Position:
Clinical Assistant Professor
Division:
Medical Oncology
Education:
University of Toronto, B.Sc. (Honours) Human Biology
University of Toronto, MD
Recent Publications:

•Robinson AG, Turbin D, Thomson T, Yorida E, Ellard S, Bajdik C, Huntsman D, Gelmon K. Molecular predictive factors in patients receiving trastuzumab-based chemotherapy for metastatic disease. Clinical Breast Cancer. 7(3):254-61, Aug 2006.
•Chi KN. Ellard SL. Hotte SJ. Czaykowski P. Moore M. Ruether JD. Schell AJ. Taylor S. Hansen C. Gauthier I. Walsh W. Seymour L. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Annals of Oncology. 19(4):746-51, 2008 Apr.
•Hoskins PJ, Le N, Ellard S, Lee U, Martin LA, Swenerton KD, Tinker AV. Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience. Gynecologic Oncology. 108(1):58-62, 2008 Jan.
•Vu T, Ellard S, Speers CH, Taylor SCM, de Lemos ML, Hu F, Kuik K & Olivotto IA. Survival outcome and cost effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation. Annals of Oncology. 19(3):461-4, 2008 Mar.
•McArthur HL, Gelmon KA, Olivotto IA, Speers CH, Ellard SL, O’Reilly SE, Kennecke HF. The effectiveness of a letter notification program for women with early stage breast cancer eligible for extended adjuvant letrozole. Journal of Clinical Oncology. 1388-1393. March 2009.
•Chia S, Dent S, Ellard S, Ellis PM, Vandenberg T, Gelmon K, Powers J, Walsh W, Seymour L, Eisenhauer EA. Phase II Trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin Cancer Res. 15 708-713, 2009.
•Ellard SL, Clemons MJ, Gelmon K, Norris BD, Kennecke HF, Chia SK, Pritchard KI, Eisen A, Vandenberg T, Taylor M, Sauerbrei EE, Mishaeli M, Huntsman D, Walsh WR, Olivo M, McIntosh L, Seymour L. A Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer; National Cancer Institute of Canada Clinical Trials Group IND.163. Journal of Clinical Oncology 27(27):4536-41, September 2009.
•Biagi JJ;Oza AM; ChalChal HI; Grimshaw R; Ellard SL; Lee U; Hirte H; Sederias J; Ivy SP; Eisenhauer EA. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Annals of Oncology 2010.
•Hirte H, Oza A, Swenerton K, Ellard SL, Grimshaw R, Fisher B, Tsao M, Seymour L A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149) Gynecologic Oncology:118(3):308 -312, 2010.
•Michels J, Ellard SL, Le L, Kollmannsberger C, Murray N, Tomlinson Guns ES, Carr R, Chi KN. A phase 1B study of ABT-751 in combination with docetaxel in patients with advanced castration resistant prostate cancer. Annals of Oncology 21:305-311. 2010.
•de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, and Scher HI. Abiraterone and Increased Survival in Metastatic Prostate Cancer. NEJM. 364:1995-2005, May 26, 2011.
•Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers. PLoS ONE 2011;6(7):e21121.oi:10.1371/journal.pone.